DUBLIN–(BUSINESS WIRE)–The “Juvenile
Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Juvenile Macular Degeneration (Stargardt Disease)
(Ophthalmology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.
The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)
pipeline guide also reviews of key players involved in therapeutic
development for Juvenile Macular Degeneration (Stargardt Disease) and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase II, Phase I,
Preclinical and Discovery stages are 1, 4, 1, 10 and 2 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 3
molecules, respectively.
Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)
pipeline guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive
advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Juvenile Macular Degeneration (Stargardt Disease)
(Ophthalmology). -
The pipeline guide reviews pipeline therapeutics for Juvenile Macular
Degeneration (Stargardt Disease) (Ophthalmology) by companies and
universities/research institutes based on information derived from
company and industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Juvenile Macular
Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and
enlists all their major and minor projects. -
The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt
Disease) (Ophthalmology) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Juvenile Macular Degeneration (Stargardt Disease)
(Ophthalmology)
Key Topics Covered:
- Introduction
- Report Coverage
- Juvenile Macular Degeneration (Stargardt Disease) – Overview
-
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics
Development - Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
-
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics
Assessment - Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Juvenile Macular Degeneration (Stargardt Disease) – Companies Involved
in Therapeutics Development
- Acucela Inc
- Alkeus Pharmaceuticals Inc
- Astellas Pharma Inc
- Biophytis SA
- Copernicus Therapeutics Inc
- Generation Bio Corp
- Grupo Ferrer Internacional SA
- Katairo GmbH
- Lin Bioscience Inc
- Nightstar Therapeutics PLC
- Ophthotech Corp
- ProQR Therapeutics NV
- Sanofi
- Spark Therapeutics Inc
- WAVE Life Sciences Ltd
Juvenile Macular Degeneration (Stargardt Disease) – Drug Profiles
- ALK-001 – Drug Profile
- ASP-7317 – Drug Profile
- avacincaptad pegol sodium – Drug Profile
- BIO-201 – Drug Profile
- emixustat hydrochloride – Drug Profile
- FAB-111 – Drug Profile
- Gene Therapy 1 to Activate ABCA4 for Stargardt Disease – Drug Profile
-
Gene Therapy for Leber’s Congenital Amaurosis and Stargardt Disease –
Drug Profile - Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile
- Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile
- Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile
- Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile
- LBS-008 – Drug Profile
- NSRABCA-4 – Drug Profile
- Oligonucleotides to Activate ABCA4 for Stargardt Disease – Drug Profile
- QRX-1011 – Drug Profile
-
Recombinant Enzyme for Age Related Macular Degeneration and Stargardt
Disease – Drug Profile - SAR-422459 – Drug Profile
- Stem Cell Therapy for Ophthalmic Disorders – Drug Profile
- VM-200 – Drug Profile
- Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1ci52j
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Optical
Disorders Drugs